about
sameAs
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trialHematopoietic stem cell transplantation: a global perspectiveSevere events in donors after allogeneic hematopoietic stem cell donationFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaDonor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies.Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013.Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation.Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow TraTreatment of Aplastic Anemia.Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT).A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia.Cytopenia and hematopoietic recovery after low intensity conditioning transplants.Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants.Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.Effect of beta-blockers, Ca2+ antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia.Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 RA comparison between ALG and bone marrow transplantation in treatment of severe aplastic anemia.[Establishing an umbilical cord blood bank for unrelated allogenic stem cell transplantation][Thrombotic thrombocytopenic purpura: report on 5 cases and current therapy concepts][Bernard-Soulier thrombocytopenia: clinical significance of a rare disorder]Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases.Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantationAutologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease.Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.Multiple cotton wool spots following bone marrow transplantation for treatment of acute lymphatic leukaemia.In utero hematopoietic stem cell transfer: current status and future strategies.From autoimmunity to stem cell transplantation.Hematopoietic stem cell transplantation for autoimmune disorders.Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technologyAutologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League AgaImpact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia.Mannose-binding lectin levels and major infections in a cohort of very long-term survivors after allogeneic stem cell transplantationSibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapseValue of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor.
P50
Q19862843-E1D921AE-7A97-42A3-A6F8-1624D43C6F5BQ24624697-617E5D55-B9D8-498D-81B2-B304497F43B4Q24649646-E0233C2D-4307-4D05-8298-CC5BFFD54940Q29614280-75AD30BA-D1A4-4DAC-9588-DFAABF47582FQ30423572-7745558E-1580-4799-B123-CE5B62403C77Q30636005-76A26F63-5F55-45BF-B9BB-0509FD97E0A1Q30990142-84EDDFCB-E8A5-4ACA-9B6D-B2F55FA8F84AQ31034167-028DB594-CAE4-4F99-8872-B44DD8D110AAQ33329342-4755F273-D8C2-4C63-9685-0BA039CB65C3Q33343954-B5829485-FF15-4EB2-8ED8-DFAD3F2F8CBFQ33343973-E3E4990D-B58E-43ED-BA28-733AA5605CCAQ33344858-3BA665B4-AD95-4DE2-A313-26820B1B921FQ33362158-FFA01B2B-1F20-40B2-9171-683AFBAE8E2EQ33368614-BC3D054D-1845-4105-8D97-8D7A88EDF8D5Q33370159-E2055F32-9E64-4768-BC33-0F1413AA3EB4Q33373889-350636F8-1767-450B-BE69-CFDFD130B299Q33387124-191055E8-885E-4597-AC93-A7367BB15278Q33396720-36C18A75-7929-4179-AE31-29F21FDD8489Q33401216-95338394-EC59-4E31-B37B-2556138C1653Q33450216-442DC748-3712-4D87-8E5D-A86FF08ED599Q33464693-D6289722-EB37-4A84-B044-8EF656CBFB1EQ33485368-6DED53BE-F883-4B33-A78E-98A8EADABB90Q33498261-33351BC8-B429-4079-97CB-299DE85D446DQ33503546-676EE290-3488-45DC-B464-61C1B92481CBQ33558733-F4D35438-63EA-44E8-AA12-FE1A71E58CEDQ33579379-5D06D4D1-8D9A-4BEA-90BA-A9C73F7171F7Q33632260-1BEBDBB4-0119-4724-B798-AA630DDD3F58Q33644054-E88D536B-481F-4D6A-9821-DC7FD0AC58A1Q33700729-2FA52AC4-B4DB-4DFE-B044-4B9B81CD77C9Q33706249-1268F80B-F6AA-4352-9297-68968A9941AAQ33765235-F3839D5D-50BE-4C48-A981-A3C644FA4C7AQ33800486-04C2B71D-E018-4781-B3B8-81C2BF1C453DQ33876528-4C7C055D-20ED-47F3-A19E-5709B9476B3BQ33886172-6D04D04F-EDE6-430C-A5D2-75A8EFB7A008Q34032256-64EEC27A-7D91-4257-B9FA-D9BC5F231988Q34087133-1FC3479A-EF55-4B42-B27C-436EBA4E99F7Q34166581-C52E556C-BFD7-4196-AED7-A50F7D70D117Q34183674-BF03C3F7-8946-493A-A53D-1C176CCB6A15Q34353744-1FA20C4A-1C72-4084-A896-1B48ADDCC81CQ34451605-E1D4CEF3-DC15-45B9-8DED-97C24343B760
P50
description
auteur
@nl
name
Alois Gratwohl
@ast
Alois Gratwohl
@en
Alois Gratwohl
@es
Alois Gratwohl
@nl
type
label
Alois Gratwohl
@ast
Alois Gratwohl
@en
Alois Gratwohl
@es
Alois Gratwohl
@nl
altLabel
A Gratwohl
@en
prefLabel
Alois Gratwohl
@ast
Alois Gratwohl
@en
Alois Gratwohl
@es
Alois Gratwohl
@nl
P106
P21
P31
P496
0000-0002-4821-1726